Durvalumab ATLANTIC trial supports clinical activity and AstraZeneca's overall immuno-oncology strategy
Durvalumab demonstrated clinical activity and durable responses in 3rd-line or later stage NSCLC patients; full data to be presented at a scientific congress in 2016
Durvalumab monotherapy and combination trials on track in multiple cancers, including 1st-line therapy for NSCLC, head & neck and bladder cancers
18 December 2015
AstraZeneca today provided an update on preliminary findings from the ATLANTIC trial of durvalumab as 3rd-line or later stage therapy in patients with locally advanced or metastatic programmed death ligand-1 (PD-L1) positive non-small cell lung cancer (NSCLC) that lacks epidermal growth factor receptor (EGFR) or ALK alterations. An initial analysis supports durvalumab's clinical activity, with durable responses and an established safety profile in these difficult-to-treat patients.
ATLANTIC investigated the efficacy and tolerability of durvalumab in patients who received at least two prior systemic treatment regimens including platinum-based chemotherapy, and who have limited options for further therapy. A full evaluation of the data is ongoing and the results will be presented at a scientific congress in 2016.
Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: "As we have seen in other studies, durvalumab has demonstrated expected clinical activity and durable response in these heavily pre-treated patients. As previously communicated, the treatment and regulatory landscape in lung cancer is evolving. We now believe it is unlikely that ATLANTIC can be used for regulatory submission as a monotherapy, but we will make that determination following a full analysis of the data. Durvalumab is a cornerstone of our immuno-oncology portfolio with a fast advancing development programme focused primarily on novel combinations."
A comprehensive durvalumab registration programme is underway across multiple tumour types, stages of disease, and lines of therapy both as monotherapy and in combination. This forms part of AstraZeneca's late-stage immuno-oncology programme and includes more than 9,000 patients in 16 clinical trials in lung, bladder, head & neck, and other cancers, summarised below.
DURVALUMAB DEVELOPMENT PROGRAMME
Status as of Year-To-Date and Q3 2015 Financial results on 5 November 2015
Next update with FY 2015 Results on 4 February 2016
LUNG CANCER
|
Name |
Phase |
Line of treatment |
Population |
Design |
Timelines |
Status |
|
Early disease |
||||||
| Monotherapy | ||||||
| ADJUVANT | III | N/A | Stage Ib-IIIa NSCLC | durvalumab vs placebo | Data expected 2020 | Recruiting |
| PACIFIC | III | N/A | Stage III unresect-able NSCLC | durvalumab vs placebo | Data expected 2017 | Recruiting |
| Advanced/metastatic disease | ||||||
| Monotherapy | ||||||
| ATLANTIC | II | 3rd line | PD-L1 pos. NSCLC | durvalumab (single arm) | Full data 2016 | - |
| Combination therapy | ||||||
| ARCTIC | III | 3rd line | NSCLC | durvalumab vs SoC (PD-L1 pos.) or durvalumab vs tremelimumab vs durva + treme vs SoC (PD-L1 neg.) | Data expected 2017 | Recruiting |
| MYSTIC | III | 1st line | NSCLC (PFS endpoint) | durvalumab vs durva + treme vs SoC | Data expected 2017 | First patient dosed |
| NEPTUNE | III | 1st line | NSCLC (OS endpoint) | durva + treme vs SoC | Data expected 2018 | Awaiting first patient dosed |
| - | III | 1st line | NSCLC | durvalumab + chemotherapy +/- tremelimumab | In preparation | |
| CAURAL | III | 2nd line | T790M+ NSCLC | osimertinib vs osimertinib + durvalumab | Data expected 2018 | Initiated enrolment; currently on partial clinical hold to characterise incidence of interstitial lung disease |
METASTATIC HEAD AND NECK CANCER
|
Name |
Phase |
Line of treatment |
Population |
Design |
Timelines |
Status |
| Monotherapy | ||||||
| HAWK | II | 2nd line | PD-L1 pos. SCCHN | durvalumab (single arm) |
Data expected H2 2016 |
Recruiting Indication granted FDA Fast Track designation |
| Combination therapy | ||||||
| CONDOR | II | 2nd line | PD-L1 neg. SCCHN | durvalumab vs tremelimumab vs durva + treme | Data expected 2017 | Recruiting |
| EAGLE | III | 2nd line | SCCHN | durvalumab vs durva + treme vs SoC | Data expected 2018 | In preparation |
| KESTREL | III | 1st line | SCCHN | durvalumab vs durva + treme vs SoC | Data expected 2018 | In preparation |
METASTATIC BLADDER CANCER
|
Name |
Phase |
Line of treatment |
Population |
Design |
Timelines |
Status |
| DANUBE | III | 1st line | Cisplatin chemo-therapy-eligible/ineligible | durvalumab vs durva + treme vs SoC |
Data expected 2018 |
First patient dosed |
OTHER TUMOUR TYPES
|
Name |
Phase |
Line of treatment |
Indication |
Design |
Timelines |
Status |
| - | II | 2nd/3rd line | Metastatic gastric cancer | durvalumab vs tremelimumab vs durva + treme |
|
In preparation |
| - | II | 2nd line | Unresect-able liver cancer | durvalumab vs tremelimumab vs durva + treme | In preparation | |
| ALPS | II | 2nd line | Unresect-able liver cancer | durva + treme (single arm) | In preparation |
SoC = Standard of Care, PFS = Progression Free Survival, OS = Overall Survival
NOTES TO EDITORS
About durvalumab (MEDI4736)
Durvalumab is an investigational human monoclonal antibody directed against PD-L1. Signals from PD-L1 help tumours avoid detection by the immune system. Durvalumab blocks these signals, countering the tumour's immune-evading tactics. Durvalumab is being developed, alongside other immunotherapies, to empower the patient's immune system and attack the cancer. Durvalumab is being investigated in an extensive clinical trial programme, as monotherapy or in combination with tremelimumab, in NSCLC, head and neck, gastric, pancreatic, bladder and blood cancers.
About the ATLANTIC trial
ATLANTIC is a Phase II, non-comparative, open-label, multi-centre, international trial of durvalumab in patients with locally advanced or metastatic NSCLC (Stage IIIB-IV) who have received at least two prior systemic treatment regimens including one platinum-based chemotherapy regimen.
About AstraZeneca in Oncology
Oncology is a therapy area in which AstraZeneca has deep-rooted heritage. It will be potentially transformational for the company's future, becoming the sixth growth platform. Our vision is to help patients by redefining the cancer treatment paradigm and one day eliminate cancer as a cause of death. By 2020, we are aiming to bring six new cancer medicines to patients.
Our broad pipeline of next-generation medicines is focused on four main disease areas – lung, ovarian, breast and haematological cancers. These are being targeted through four key platforms – immuno-oncology, the genetic drivers of cancer and resistance, DNA damage repair and antibody drug conjugates.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit www.astrazeneca.com.
CONTACTS
Media Enquiries
| Esra Erkal-Paler | (UK/Global) | +44 20 7604 8030 |
| Vanessa Rhodes | (UK/Global) | +44 20 7604 8037 |
| Ayesha Bharmal | (UK/Global) | +44 20 7604 8034 |
| Karen Birmingham | (UK/Global) | +44 20 7604 8120 |
| Jacob Lund | (Sweden) | +46 8 553 260 20 |
| Michele Meixell | US | +1 302 885 2677 |
Investor Enquiries
UK
| Thomas Kudsk Larsen | +44 20 7604 8199 | +44 7818 524185 | |
| Eugenia Litz | RIA | +44 20 7604 8233 | +44 7884 735627 |
| Nick Stone | CVMD | +44 20 7604 8236 | +44 7717 618834 |
| Craig Marks | ING | +44 20 7604 8591 | +44 7881 615764 |
| Christer Gruvris | +44 20 7604 8126 | +44 7827 836825 |
US
| Lindsey Trickett | Oncology, ING | +1 301 398 5118 | +1 240 543 7970 |
| Mitch Chan | Oncology | +1 301 398 1849 | +1 240 477 3771 |
| Dial / Toll-Free | +1 301 398 3251 | +1 866 381 7277 |
Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and Metabolic Disease, ING - Infection, Neuroscience and Gastrointestinal